Annual report pursuant to Section 13 and 15(d)

SUBSEQUENT EVENTS

v3.20.1
SUBSEQUENT EVENTS
12 Months Ended
Dec. 31, 2019
SUBSEQUENT EVENTS  
Note 20 - SUBSEQUENT EVENTS

In January 2020, the Company was awarded a second year of funding from the National Institute on Drug Abuse ( NIDA ) to support the development of a 3-month implantable depot pellet of naltrexone for the treatment of Opioid Use Disorder, which the Company refers to as BICX102. The second-year grant provides for $2,831,838 in funding subject to the terms and conditions specified in the grant, including satisfactory progress of project and the availability of funds.

 

As of February 28, 2020 the Company issued an aggregate of 12,905 shares of its common stock for consulting services and one employee valued at $35,776.

 

In December 2019, a novel strain of coronavirus (COVID-19) surfaced. The spread of COVID-19 around the world in the first quarter of 2020 has caused significant volatility in U.S. and international markets. There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the U.S. and international economies and, as such, the Company is unable to determine if it will have a material impact to its operations.